

# Daniel Umbricht

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7310782/publications.pdf>

Version: 2024-02-01

82  
papers

9,484  
citations

81900

39  
h-index

69250

77  
g-index

86  
all docs

86  
docs citations

86  
times ranked

11918  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. <i>Nature Genetics</i> , 2018, 50, 668-681.	21.4	2,224
2	Antibodies against $\beta$ -Amyloid Slow Cognitive Decline in Alzheimer's Disease. <i>Neuron</i> , 2003, 38, 547-554.	8.1	779
3	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
4	Mismatch negativity in schizophrenia: a meta-analysis. <i>Schizophrenia Research</i> , 2005, 76, 1-23.	2.0	636
5	Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers. <i>Archives of General Psychiatry</i> , 2000, 57, 1139.	12.3	552
6	Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 958-966.	4.3	268
7	How specific are deficits in mismatch negativity generation to schizophrenia?. <i>Biological Psychiatry</i> , 2003, 53, 1120-1131.	1.3	237
8	Mismatch negativity predicts psychotic experiences induced by nmda receptor antagonist in healthy volunteers. <i>Biological Psychiatry</i> , 2002, 51, 400-406.	1.3	217
9	Effects of clozapine on auditory event-related potentials in schizophrenia. <i>Biological Psychiatry</i> , 1998, 44, 716-725.	1.3	209
10	Cognitive Functioning in the Schizophrenia Prodrome. <i>Schizophrenia Bulletin</i> , 2007, 33, 761-771.	4.3	202
11	Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 637.	11.0	185
12	Electrophysiological Indices of Automatic and Controlled Auditory Information Processing in First-Episode, Recent-Onset and Chronic Schizophrenia. <i>Biological Psychiatry</i> , 2006, 59, 762-772.	1.3	175
13	Clozapine and Haloperidol in Moderately Refractory Schizophrenia. <i>Archives of General Psychiatry</i> , 2001, 58, 965.	12.3	163
14	Effects of the 5-HT <sub>2A</sub> Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia. <i>Neuropsychopharmacology</i> , 2003, 28, 170-181.	5.4	154
15	Postictal and chronic psychoses in patients with temporal lobe epilepsy. <i>American Journal of Psychiatry</i> , 1995, 152, 224-231.	7.2	150
16	Translating Glutamate: From Pathophysiology to Treatment. <i>Science Translational Medicine</i> , 2011, 3, 102mr2.	12.4	147
17	Ultra high-risk state for psychosis and non-transition: A systematic review. <i>Schizophrenia Research</i> , 2011, 132, 8-17.	2.0	137
18	The Prevalence of Acute Extrapyramidal Signs and Symptoms in Patients Treated With Clozapine, Risperidone, and Conventional Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 69-75.	2.2	135

#	ARTICLE	IF	CITATIONS
19	The FDA-NIMH-MATRICES Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?. Schizophrenia Bulletin, 2011, 37, 1209-1217.	4.3	121
20	Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. Molecular Psychiatry, 2020, 25, 1430-1446.	7.9	116
21	Effects of risperidone on auditory event-related potentials in schizophrenia. International Journal of Neuropsychopharmacology, 1999, 2, 299-304.	2.1	112
22	Defining subjects at risk for psychosis: A comparison of two approaches. Schizophrenia Research, 2006, 81, 83-90.	2.0	101
23	Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [ <sup>11</sup> C]ABP688 positron emission tomography. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 737-742.	7.1	100
24	High remission rates from an initial ultra-high risk state for psychosis. Schizophrenia Research, 2010, 116, 168-172.	2.0	89
25	The Genetic Architecture of Depression in Individuals of East Asian Ancestry. JAMA Psychiatry, 2021, 78, 1258.	11.0	88
26	Does Childhood Trauma Moderate Polygenic Risk for Depression? A Meta-analysis of 5765 Subjects From the Psychiatric Genomics Consortium. Biological Psychiatry, 2018, 84, 138-147.	1.3	87
27	Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology, 2013, 64, 337-346.	4.1	86
28	An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biological Psychiatry, 2017, 82, 322-329.	1.3	84
29	A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine, 2019, 11, .	12.4	83
30	Cerebral blood flow predicts differential neurotransmitter activity. Scientific Reports, 2018, 8, 4074.	3.3	78
31	A Randomized, Placebo-Controlled Study Investigating the Nicotinic $\alpha 7$ Agonist, RG3487, for Cognitive Deficits in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1568-1577.	5.4	71
32	A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder. Neuropsychopharmacology, 2017, 42, 1914-1923.	5.4	63
33	Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Research, 2004, 1019, 189-200.	2.2	61
34	Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biological Psychiatry, 1996, 39, 249-254.	1.3	60
35	Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome. Schizophrenia Research, 2012, 142, 108-115.	2.0	59
36	Early Auditory Sensory Processing Deficits in Mouse Mutants with Reduced NMDA Receptor Function. Neuropsychopharmacology, 2008, 33, 1680-1689.	5.4	55

#	ARTICLE	IF	CITATIONS
37	Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2013, 38, 504-512.	5.4	47
38	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 328-333.	2.0	46
39	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. <i>Molecular Psychiatry</i> , 2021, 26, 2457-2470.	7.9	44
40	Declining transition rates to psychosis: The role of diagnostic spectra and symptom overlaps in individuals with attenuated psychosis syndrome. <i>Schizophrenia Research</i> , 2014, 159, 292-298.	2.0	43
41	Cognitive Behavior Therapy for Weight Gain. <i>American Journal of Psychiatry</i> , 2001, 158, 971-971.	7.2	38
42	A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. <i>Frontiers in Neurology</i> , 2021, 12, 705407.	2.4	36
43	The International Study on General Practitioners and Early Psychosis (IGPS). <i>Schizophrenia Research</i> , 2009, 108, 182-190.	2.0	35
44	Subclinical hallucinations in adolescent outpatients: An outcome study. <i>Schizophrenia Research</i> , 2009, 108, 265-271.	2.0	35
45	Placebo Response and Practice Effects in Schizophrenia Cognition Trials. <i>JAMA Psychiatry</i> , 2017, 74, 807.	11.0	34
46	Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. <i>Schizophrenia Research</i> , 2017, 190, 172-179.	2.0	33
47	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	2.2	31
48	Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	28
49	Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. <i>Biological Psychiatry</i> , 2020, 87, 419-430.	1.3	27
50	In Search of Biomarkers for Autism Spectrum Disorder. <i>Autism Research</i> , 2018, 11, 1567-1579.	3.8	22
51	Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient. <i>Chimia</i> , 2018, 72, 477.	0.6	21
52	Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis. <i>Schizophrenia Bulletin</i> , 2019, 45, 57-68.	4.3	18
53	Association of Whole-Genome and NETRIN1 Signaling Pathway–Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 91-100.	1.5	16
54	Developing services for the early detection of psychosis. <i>European Child and Adolescent Psychiatry</i> , 2007, 16, 96-103.	4.7	15

#	ARTICLE	IF	CITATIONS
55	Social Anxiety in Children and Adolescents With Autism Spectrum Disorders Contribute to Impairments in Social Communication and Social Motivation. <i>Frontiers in Psychiatry</i> , 2020, 11, 710.	2.6	14
56	Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin. <i>Quality of Life Research</i> , 2016, 25, 201-211.	3.1	13
57	Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: Preliminary findings. <i>Biological Psychiatry</i> , 1995, 37, 52-55.	1.3	12
58	Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease. <i>Psychiatric Genetics</i> , 2002, 12, 155-160.	1.1	11
59	Deep Learning-Based Human Activity Recognition for Continuous Activity and Gesture Monitoring for Schizophrenia Patients With Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2020, 11, 574375.	2.6	11
60	Clozapine and Risperidone in Moderately Refractory Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 628-634.	2.2	11
61	Prodromal schizophrenia in primary care: a randomised sensitisation study. <i>British Journal of General Practice</i> , 2010, 60, e353-e359.	1.4	9
62	Predictors of response to clozapine in a long-term double blind treatment study. <i>Schizophrenia Research</i> , 1997, 24, 189.	2.0	7
63	Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 4412-4430.	2.7	6
64	Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	5
65	Nailing the Right Dose! The Key for Developing Glycine Transporter Inhibitors for Schizophrenia. <i>Biological Psychiatry</i> , 2018, 84, 394-395.	1.3	4
66	Reading the Mind in the Eyes in Autistic Adults is Modulated by Valence and Difficulty: An InFoR Study. <i>Autism Research</i> , 2021, 14, 380-388.	3.8	4
67	The effect of risperidone on reward-related brain activity is robust to drug-induced vascular changes. <i>Human Brain Mapping</i> , 2021, 42, 2766-2777.	3.6	4
68	Effectiveness of clozapine in treatment resistant schizophrenia. <i>Schizophrenia Research</i> , 1997, 24, 187.	2.0	3
69	First improvement with clozapine: How patient should we be?. <i>Schizophrenia Research</i> , 1997, 24, 188.	2.0	3
70	The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. <i>Schizophrenia Research</i> , 1997, 24, 265-266.	2.0	3
71	Is Elevated Striatal Dopamine Function a Prodromal Sign of Schizophrenia?. <i>Archives of General Psychiatry</i> , 2009, 66, 915.	12.3	3
72	5.13 Effects of Balovaptan on Health-Related Quality of Life of Adult Men With ASD: Results From a Phase 2 Randomized Double-Blind Placebo Controlled Study (Vanilla). <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, S231.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Optimizing Behavioral Paradigms to Facilitate Development of New Treatments for Anhedonia and Reward Processing Deficits in Schizophrenia and Major Depressive Disorder: Study Protocol. <i>Frontiers in Psychiatry</i> , 2020, 11, 536112.	2.6	3
74	Clozapine vs. haloperidol: Drug intolerance in a controlled six month trial. <i>Schizophrenia Research</i> , 1997, 24, 268.	2.0	2
75	Discriminant value of repetitive behaviors in families with autism spectrum disorder and obsessional compulsive disorder probands. <i>Autism Research</i> , 2021, 14, 2373-2382.	3.8	2
76	Auditory event-related potentials (ERP) in first episode and chronic schizophrenia. <i>Schizophrenia Research</i> , 1997, 24, 238-239.	2.0	0
77	Event-related potentials (ERP) during a visual working memory task in first episode and chronic schizophrenia. <i>Schizophrenia Research</i> , 1997, 24, 239.	2.0	0
78	Primary care and the early phases of schizophrenia in the Czech Republic. <i>Epidemiologia E Psichiatria Sociale</i> , 2010, 19, 243-250.	0.9	0
79	Poster #219 A POST-HOC ANALYSIS OF THE NEGATIVE SYMPTOM FACTOR SCORE IN A PROOF-OF-CONCEPT WITH A GLYCINE REUPTAKE INHIBITOR (GRI) IN SCHIZOPHRENIA. <i>Schizophrenia Research</i> , 2012, 136, S360.	2.0	0
80	O11.3. DEEP LEARNING-BASED HUMAN ACTIVITY RECOGNITION FOR CONTINUOUS ACTIVITY AND GESTURE MONITORING FOR SCHIZOPHRENIA PATIENTS WITH NEGATIVE SYMPTOMS. <i>Schizophrenia Bulletin</i> , 2019, 45, S194-S195.	4.3	0
81	Matrix metalloproteinase 9 levels and parvalbumin positive interneuron dysfunction. <i>Neuropsychopharmacology</i> , 2021, , .	5.4	0
82	LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMERâ€™S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. <i>THE JOURNAL OF PREVENTION OF ALZHEIMERâ€™S DISEASE</i> , 2020. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-2.	2.7	0